Major Pharmaceutical Markets of the Middle East (Related Reports)

Major Pharmaceutical Markets of the Middle East


February 14, 2009
89 Pages - SKU: URC2109730
License type:
Online Download      US $2,030.00
Hard Copy Mail Delivery      US $2,110.00
Global Site License Fulfilled by Publisher      US $11,760.00
Pharmaceuticals in Turkey: ISIC 2423
3/28/2014 | published by: Euromonitor International
Pharmaceuticals in Turkey: ISIC 2423 Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to the size and shape of the Pharmaceuticals market at a  |  read more...
$600.00
Vietnam Pharmaceuticals and Healthcare Report Q2 2014
4/2/2014 | published by: Business Monitor International
Vietnam Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Vietnam's reliance on imported drugs (both generic and patented) will continue toprovide ample commercial opportunities for foreign drugmakers. However, the population's concerns overdrug quality means that only  |  read more...
$1,295.00
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2014
4/2/2014 | published by: Business Monitor International
United Arab Emirates Pharmaceuticals and Healthcare Report Q2 2014 BMI View: UAE's increasing investment from public and private sectors in its healthcare industry is set tobring improved standards of care and increased access to medicines, as  |  read more...
$1,295.00
Ghana Pharmaceuticals and Healthcare Report Q2 2014
4/2/2014 | published by: Business Monitor International
Ghana Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Although our USD headline forecasts for Ghana in Q2014 have been revised lower, this islargely due to currency fluctuations. We remain positive towards Ghana's healthcare and pharmaceuticalmarkets  |  read more...
$1,295.00
Canada Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
Canada Pharmaceuticals and Healthcare Report Q2 2014 BMI View: On the back of more promising a macroeconomic outlook in 2014, we believe the Canadianpharmaceutical and healthcare market will be more attractive to pharmaceutical companies. Althoughdrugmakers will  |  read more...
$1,295.00
United States Pharmaceuticals and Healthcare Report Q2 2014
3/5/2014 | published by: Business Monitor International
United States Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Pharmaceutical companies are facing far greater opportunities and challenges thanthe Affordable Care Act (ACA). Healthcare reform in the US could have sought significant monetarycontributions from drugmakers,  |  read more...
$1,295.00
Bangladesh Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
Bangladesh Pharmaceuticals and Healthcare Report Q2 2014 BMI View: While the government of Bangladesh has made significant progress in improving healthcareaccess for its population, almost two thirds of healthcare spending is sourced privately out-of -pocket -highlighting  |  read more...
$1,295.00
France Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
France Pharmaceuticals and Healthcare Report Q2 2014 BMI View: A number of biologics will lose patent protection between now and 2015, which means thatFrance's biosimilar substitution legislation will pave the way to cost savings in the  |  read more...
$1,295.00
Peru Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
Peru Pharmaceuticals and Healthcare Report Q2 2014 BMI View: Peru will offer longer-term growth opportunities to foreign pharmaceutical companies. Although per capita medicine spending in the country is among the lowest in Latin America,pharmaceutical companies can generate  |  read more...
$1,295.00
Uganda Pharmaceuticals and Healthcare Report Q2 2014
3/12/2014 | published by: Business Monitor International
Uganda Pharmaceuticals and Healthcare Report Q2 2014 BMI View: We do not expect Uganda's reliance on imported drugs to decrease, even though thegovernment has been encouraging the domestic production of drugs. Additionally, export growth will beslow  |  read more...
$1,295.00